Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Long-term outcome of a treat-to-target strategy in late-onset rheumatoid arthritis with chronic lung disease: 5-year results of a prospective observational study

Fig. 1

Treatment of LORA patients with and without CLD. Time variation in the proportion of patients with and without CLD taking MTX, GCs, bDMARDs, Tacrolimus, and SASP or BUC. LORA: late-onset rheumatoid arthritis, CLD: chronic lung disease, MTX: methotrexate, GCs: glucocorticoids, bDMARDs: biological disease-modifying antirheumatic drugs (Infliximab, Etanercept, Adalimumab, Golimumab, Certolizumab, Tocilizumab, Abatacept), SASP: Salazosulfapyridine, BUC: Bucillamine

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us